Early Developability Assessment For Smarter Antibody Selection

A specialized developability assessment platform helps biopharmaceutical teams quickly evaluate antibody candidates, reduce development risks, and make better decisions with very little material. By combining advanced lab testing with in‑silico modeling, it identifies potential issues with stability, manufacturability, and formulation early, long before costly development steps.

The service includes three package options—candidate selection, high‑concentration suitability, and formulation sensitivity. Each one focuses on a different early‑development challenge, allowing teams to screen molecules, uncover liabilities, and choose the strongest candidates. With sample requirements as low as a few milligrams, even early programs can gain valuable insights without heavy resource use.

The platform works not only for monoclonal antibodies but also for related proteins and peptides. Support can continue beyond assessment into formulation design, preclinical preparation, and later‑stage development. The goal is to provide a smooth path from discovery to a stable, manufacturable, and patient‑ready drug product.